News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
The best metric is not weight, but a particularly toxic kind of fat.
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback